Melatonin in Relapsing-Remitting Multiple Sclerosis Patients

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether melatonin is effective in the treatment of relapsing-remitting multiple sclerosis patients as a supplement to the main disease-modifying drugs.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tehran University of Medical Sciences
• Treatments: Melatonin

Criteria

Inclusion Criteria:

• definite diagnosis of relapsing-remitting multiple sclerosis

• EDSS <=5

• at least 6months consumption of interferon beta 1a

Exclusion Criteria:

• illiteracy

• evidence of Nystagmus or visual acuity lower than 5/10 in each of the eyes

• relapse in the last 3 months

• pregnancy or deciding to become pregnant during the following year

• regulatory consumption of warfarin, nifedipine, nonsteroidal anti-inflammatory drugs (NSAIDs), beta-blockers, fluvoxamine, isoniazide, progestin

• history of epilepsy, stroke, major depression, endocrine, hepatic, hematologic, and nephrologic diseases